Geographical Management of Cancer Health Disparities Program

Connecting researchers and resources to eliminate cancer health disparities

People across the United States are affected by cancer in many different ways. Differences in race and ethnicity, income, geographic residence, education, healthcare access, and cancer research can create health disparities for individuals who experience these differences. The Geographical Management of Cancer Health Disparities Program (GMaP) seeks to reduce these disparities by supporting the next generation of researchers to advance the science of cancer health disparities and create health equity for all who are affected by cancer.


Attending a virtual conference this spring?

If so, GMaP Region 3 would like to provide funding to help cover registration fees. Apply for funding through our travel award form (see Travel Scholarships below) today! For questions, please contact, Miria Kano.

E-Newsletters

March 2021
January 2021
The Grant Development Process
Announcing GMaP Research Stimullus Pilot Awards

Subscribe to Region 3 News

* indicates required

Research Highlight

Dr. Joan Lewis-Wambi is an Associate Professor in the Cancer Biology Department at the University of Kansas Medical Center and a primary member of the University of Kansas Cancer Center. She has been a faculty member at KUMC since 2013. Dr. Lewis-Wambi's research focuses on understanding the pathobiology of inflammatory breast cancer (IBC) and to identify the molecular factors responsible for driving its aggressive phenotype especially in African American women. IBC is a very aggressive and lethal subtype of breast cancer that accounts for about 2-5% of all breast cancer cases diagnosed in the United States. IBC typically presents with rapid onset of painful primary skin changes and progresses to Stage IIIb/IV metastatic disease within six months. It has been shown to disproportionately affect African American women compared to other ethnic groups. Dr. Lewis-Wambi's laboratory has recently identified a novel molecular target, IFITM1, which appears to be highly expressed in IBC tumors and IBC cell lines from African American women compared to Caucasian American women. She has recently received a GMaP Region 3 pilot grant to study the biology and function of IFITM1 in IBC and to conduct a drug repurposing high throughput screen of FDA-approved drugs to selectively target IFITM1 expression in vivo using clinically relevant IBC mouse models.